I encountered three new patients this evening for whom Cialis and Viagra have proven ineffective, leading us to suggest injectable treatments. However, all three declined this option and inquired about alternative solutions. This indicates a promising market for Spontan as a viable alternative to current offerings. As a relatively new investor, I find the fluctuations in share price somewhat concerning, yet I remain patient, especially considering the number of patients under 50 seeking alternatives. Frequently, I observe that Viagra and Cialis fail to meet their needs or result in excessive side effects. We often prescribe Tadalafil, but patients end up needing additional medications to manage these side effects. The prospect of taking multiple medications daily to mitigate adverse effects is unappealing, particularly when those effects include reflux, facial flushing, severe headaches, muscle pain, and vision disturbances.
LTP Price at posting:
89.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)